Mutation of the class I β-tubulin gene does not predict response to paclitaxel for breast cancer
Authors:
- Ken-Ichi ItoKIKen-Ichi Ito
- Yoshihisa HamaYHYoshihisa Hama
- Kiyoshi ShinguKSKiyoshi Shingu
- Morihiko KimuraMKMorihiko Kimura
- Muneaki SanoMSMuneaki Sano
- Hiroshi NakagomiHNHiroshi Nakagomi
- Shin-Ichi TsuchiyaSTShin-Ichi Tsuchiya
- Minoru FujimoriMFMinoru Fujimori
- 1 July 2003
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 198 (1) , 89-97
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Paclitaxel administration on days 1 and 8 every 21 days in anthracycline-pretreated metastatic breast cancer patients. A multicenter phase II trial.Cancer Chemotherapy and Pharmacology, 2001
- Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neckCancer, 1998
- Altered β-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cellsBritish Journal of Cancer, 1998
- Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.Journal of Clinical Investigation, 1997
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Altered Expression of Mβ2, the Class II β-Tubulin Isotype, in a Murine J774.2 Cell Line with a High Level of Taxol ResistanceJournal of Biological Chemistry, 1995
- P-glycoprotein and resistance to anticancer drugsCancer, 1992
- Taxol: A new agent active in melanoma and ovarian cancer1992
- Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast CancerJNCI: Journal of the National Cancer Institute, 1991
- Taxol stabilizes microtubules in mouse fibroblast cells.Proceedings of the National Academy of Sciences, 1980